Navigation Links
Driven By Product Innovations, the U.S. Drug Delivery Device Market Will Reach Over $4.5 Billion by 2022
Date:8/6/2014

BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States drug delivery device market will grow at a strong rate to reach a value of over $4.5 billion by 2022 (including device costs only). The future of the drug delivery device market is highly dependent on the pharma industry. Because certain types of drugs are only conducive to specific delivery methods, the kinds of new drugs developed will influence the structure of and innovation in the drug delivery market going forward.

Other key findings from Decision Resources Group's coverage of the U.S. drug delivery device market:

  • Injection devices: Injection devices continue to represent the majority of revenues because diabetic patients largely adopt pen injectors over traditional drug delivery methods, such as insulin pumps or syringes. Leading companies Novo Nordisk, Sanofi and Eli Lilly are also developing new versions or more complex pen injectors, which are expected to launch within the next ten years.
  • AFREZZA inhaler: MannKind recently received approval for the AFREZZA inhaler, which is the first inhaler that can deliver insulin. Because drugs delivered via inhalers are absorbed rapidly by the body, this has the potential to disrupt the traditional insulin delivery device markets. Nonetheless, physicians will need more clinical evidence before the AFREZZA inhaler is widely adopted.
  • Active transdermal patches: Within the transdermal patch market, the development of active patches will enable the treatment of more indications by allowing larger molecules to pass through the skin barrier. The approval of Teva's Zecuity migraine patch in January 2013 represented the first active transdermal patch to become available in the United States.

Comments from Decision Resources Group Senior Analyst Carmen Chan:

  • "A number of new technologies are poised to affect the drug delivery device market in the future. For example, microneedle patches are another type of active patch under development with manufacturers focusing on vaccinations and osteoporosis treatment; both aren't commonly treated with current drug delivery devices."
  • "Subcutaneous implants represent another major product innovation because they eliminate the risk of poor patient compliance, which is currently a significant problem with drug delivery. While current implants serve niche markets, products in development will target widespread conditions like diabetes and hernias."

Additional Resources:

  • Carmen Chan has written a Medtech 360 report on this subject entitled US Markets for Drug Delivery Devices 2014.
  • Decision Resources Group's Pharmacor, which provides a commercial outlook on drugs on the market and in development, can be found here.
  • Decision Resources Group's PatientBase, which determines the total patient and drug-treated populations, can be found here.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
2. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
3. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
4. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
5. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
6. European Urological Device Market Will Be Driven By Adoption Of New Minimally Invasive Devices
7. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
8. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
9. The Medical Affairs Function Is a Key Differentiator for Pharma Product Success in Data-Driven Healthcare Market
10. New Telemedicine Market Forecasts Show Software Sales To Reach $2.5 Billion by 2018, Driven by Tablets Like Apples iPad
11. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition ... report to their offering. ... Pain Management in the U.S.: ... physical pain, emphasizing consumer survey analysis, including trends over time. ... who have selected illnesses/conditions strongly associated with physical pain and ...
(Date:3/24/2017)... SHANGHAI , March 24, 2017 /PRNewswire/ ... organization providing high-quality and cost-effective drug development ... the pharmaceutical and biotechnology industry, announced today ... ShangPharma will be consolidating the ... Organizations (CMO) under Shanghai ChemPartner. These entities ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... How to Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path ... to Learning How to Walk with God #TruthwithGrace” is the creation of published ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... A recent ... for entry into teacher preparation programs. The NCTQ report suggests, based on a review ... requirements would significantly improve teacher quality in the U.S. It argues that this higher ...
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
Breaking Medicine News(10 mins):